Kamada's rabies treatment clears Phase III with an FDA app on deck

Kamada's ($KMDA) immunoglobulin treatment for rabies met its main goal in a late-stage trial, clearing the way for an FDA application next year. The therapy, dubbed KedRAB, is a one-time protein treatment designed to halt the rabies virus in patients who have already been exposed to it. In a Phase II/III trial, Kamada's injection met its primary endpoint of noninferiority with an older immunoglobulin therapy, and that top-line success should be enough to fuel an application for FDA approval by mid-2016, the company said. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.